Intravaginally applied oxytocin improves post-menopausal vaginal atrophy

Area of Science:

• Gynecology
• Endocrinology
• Pharmacology

Background:

• Post-menopausal vaginal atrophy is a common condition characterized by thinning and dryness of vaginal tissues.
• Current treatments primarily involve local estrogen therapy, but alternatives are sought.

Purpose of the Study:

• To evaluate the efficacy of intravaginally administered oxytocin for treating post-menopausal vaginal atrophy.

Main Methods:

• A double-blinded, randomized controlled trial was conducted with 64 healthy post-menopausal women.
• Participants received either vagitocin (oxytocin) or a placebo for seven weeks.
• Efficacy was assessed through cytological evaluation, vaginal pH, histological scoring of atrophy, and symptom reporting.

Main Results:

• Vagitocin treatment significantly increased superficial cells and maturation values (p<0.03).
• Vaginal pH decreased with vagitocin 100 IU (p=0.02), and atrophy scores were reduced (p=0.03).
• The most bothersome symptom significantly improved with vagitocin 400 IU (p=0.0089), with no changes in endometrial thickness.

Conclusions:

• Intravaginal oxytocin demonstrates efficacy in treating post-menopausal vaginal atrophy.
• Oxytocin may serve as an alternative therapeutic option to local estrogen treatments.